NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
Q2 PAT Surges 109% YoY to ₹95.93 Cr; ₹4 Interim Dividend Declared
Balrampur Chini Mills reported a 12.3% YoY rise in standalone Q2 revenue from operations to ₹1,876.28 Cr, compared to ₹1,670.76 Cr in Q2 FY26. Standalone net profit for the quarter jumped 108.8% YoY to ₹95.93 Cr from ₹45.95 Cr in the previous year's quarter. The company also declared an interim dividend of ₹4.00 per share (400%) with a record date of November 11, 2026. Standalone segment results showed sugar profit before tax surging to ₹140.75 Cr, while the Polylactic Acid (PLA) division registered an operating loss of ₹5.58 Cr.
உச்சம் நம்பிக்கை
என்ன மாறியதுBalrampur Chini approved Q2 FY27 unaudited financial results and announced an interim dividend of ₹4.00 per share.
ஏன் இது முக்கியம்Demonstrates strong operational recovery and profit growth in the core sugar business, alongside stable capital return via dividends despite ongoing capex into PLA bioplastics.
Q2 Standalone Revenue: ₹1876.28 கோடிQ2 Standalone Net Profit: ₹95.93 கோடிInterim Dividend per share: ₹4.00ரெக்கார்ட் தேதி: 11th நவம்பர், 2026Q2 Net Profit vs TTM PAT: ~25.8%
📅 குறுகிய காலம்The strong YoY earnings rebound and dividend announcement are likely to support near-term sentiment leading up to the November 11 record date.
📈 நீண்ட காலம்Growth remains linked to cane availability, government ethanol policies, and the successful execution of the ₹2,000+ Cr PLA bioplastics diversification.
⚠ அபாய எச்சரிக்கைகள்
Seasonality of cane crushing and agricultural risk from monsoon variations
Government policy interventions on sugar exports and ethanol pricing
👀 கவனிக்க வேண்டியவை
Track realization trends in sugar and ethanol pricing for upcoming quarters, as well as capital expenditure progress and commercialization milestones in the new Polylactic Acid (PLA) segment.
MGL Q2 Standalone PAT Falls 29.1% YoY to ₹137.04 Cr Despite Revenue Rising 23.8%
Mahanagar Gas Limited (MGL) shared its investor presentation for Q2 FY26-27 (ended September 30, 2026), reporting standalone net revenue growth of 23.8% YoY to ₹2,537.08 Cr. However, standalone EBITDA dropped 9.8% YoY to ₹304.76 Cr as gas costs expanded to ₹42.34/SCM from ₹33.65/SCM in Q2 FY25-26, shrinking EBITDA margin from 16.49% to 12.01%. Standalone PAT declined 29.1% YoY to ₹137.04 Cr. Total sales volumes grew 6.5% YoY to 4.892 MMSCMD, led by CNG volumes of 3.552 MMSCMD.
உச்சம் நம்பிக்கை
என்ன மாறியதுRelease of MGL's investor presentation detailing Q2 and H1 FY26-27 financial and operational performance.
ஏன் இது முக்கியம்Demonstrates margin compression caused by rising input gas costs and reliance on market-priced gas, reducing profitability despite volume growth.
📅 குறுகிய காலம்Margin compression and higher gas procurement costs may weigh on market sentiment over the near term.
📈 நீண்ட காலம்Volume expansion remains steady with UEPL geographical additions, but earnings depend structurally on domestic gas allocation policies and pass-through pricing power.
⚠ அபாய எச்சரிக்கைகள்
Higher gas procurement costs impacting EBITDA per SCM (down to ₹6.77/SCM vs ₹8.00/SCM YoY)
Reduction in low-cost APM gas allocation forcing reliance on volatile spot RLNG
👀 கவனிக்க வேண்டியவை
Monitor management commentary on APM gas allocation cuts, margin recovery strategies, and potential retail price hikes in CNG to offset higher gas sourcing costs.
MapmyIndia Appoints New CTO & CPTO, Re-designates Rashmi Verma as CIO in Top Tech Reshuffle
C.E. Info Systems (MapmyIndia) announced key senior management changes along with approving its Q2 FY27 results (financial tables omitted in extract). Mrs. Rashmi Verma transitions from CTO & CHRO to Chief Innovation Officer (CIO) to lead AI adoption. Concurrently, Mr. Abhit Kalasotra has been appointed as CTO of Software Engineering, and Mr. Nitin Sagar as CPTO of Mappls AI to drive AI-native mapping. Additionally, CFO Anuj Kumar Jain takes on an added role as COO of key subsidiary Gtropy Systems, and the board approved a minor allotment of 2,334 equity shares under ESOP.
உச்சம் நம்பிக்கை
என்ன மாறியதுMapmyIndia reshuffled its technology leadership by bringing in a dedicated CTO for software engineering and a CPTO for AI platforms, while re-designating co-founder Rashmi Verma as Chief Innovation Officer.
ஏன் இது முக்கியம்The structural realignment reflects a focused push toward scaling AI-native mapping capabilities and bolstering software engineering across the group and its subsidiaries.
ESOP shares allotted: 2334ESOP issue price: Rs. 12.15/- per shareESOP face value: Rs. 2/- each
📅 குறுகிய காலம்Neutral reaction expected as the announcement primarily covers executive leadership appointments and board approvals without immediate financial alterations.
📈 நீண்ட காலம்Strengthening leadership in AI and software engineering could accelerate product innovation and bolster MapmyIndia's competitive edge in enterprise navigation and IoT platforms.
⚠ அபாய எச்சரிக்கைகள்
Integration and leadership transition risks in high-tech product divisions
Absence of P&L figures in the extract to judge concurrent quarterly operational performance
👀 கவனிக்க வேண்டியவை
Track subsequent detailed financial tables of Q2 FY27 for margin trajectory and monitor the execution of new AI-native mapping initiatives under the new technical leadership.
Exicom announced its Q2 FY27 results, reporting consolidated revenue growth of 38% sequentially to ₹388.3 crore and turning consolidated EBITDA positive to ₹1.8 crore from a loss of ₹32.7 crore in Q2 FY26. Standalone revenue climbed 21.3% YoY to ₹277 crore, driven by EVSE revenue crossing ₹100 crore for the first time. Along with results, the board approved a non-binding term sheet to divest global fast-charging subsidiary Tritium at an indicative enterprise value of USD 85 million (cash-free, debt-free). Consolidated PAT losses narrowed to ₹57.8 crore from ₹68.8 crore a year ago.
உச்சம் நம்பிக்கை
என்ன மாறியதுExicom turned consolidated EBITDA positive in Q2 FY27 and decided to divest loss-making global arm Tritium under a USD 85 million non-binding term sheet while keeping key technology licences.
ஏன் இது முக்கியம்Tritium has heavily dragged profitability (accounting for consolidated PAT losses); divesting it allows redeployment of capital toward the profitable domestic EV/critical power segments and paves a path to zero net debt.
Consolidated Revenue Q2 FY27: ₹388.3 கோடிConsolidated EBITDA Q2 FY27: ₹1.8 கோடிConsolidated PAT Q2 FY27: -₹57.8 croreIndicative Tritium Enterprise Value: USD 85 millionTritium EV vs Market Cap (~₹1876 Cr): ~38%
📅 குறுகிய காலம்Market sentiment should react favorably to EBITDA turning positive and clarity on offloading the capital-intensive Tritium asset.
📈 நீண்ட காலம்Exit from Tritium removes a major cash burn driver, refocusing Exicom on high-growth Indian EVSE demand and stable telecom power infrastructure.
⚠ அபாய எச்சரிக்கைகள்
Tritium divestment is currently at a non-binding term sheet stage and subject to confirmatory due diligence and definitive agreements
Consolidated PAT remains significantly negative at -₹57.8 crore in Q2 FY27
👀 கவனிக்க வேண்டியவை
Track the signing of definitive agreements and closing timeline for the Tritium divestment, alongside monitoring if consolidated EBITDA sustains positive territory without Tritium's drag.
Mold-Tek Tech Q2 PAT surges 197% YoY to ₹9.62 Cr; H1 PAT rises 4.8x to ₹18.62 Cr
Mold-Tek Technologies reported strong performance for Q2 FY27, with consolidated revenue rising 51.2% YoY to ₹60.81 Cr and PAT surging 197% YoY to ₹9.62 Cr. For H1 FY27, consolidated revenue increased 63.7% YoY to ₹120.35 Cr, while PAT surged 4.8 times to ₹18.62 Cr, already surpassing total FY26 net profit of ₹10.09 Cr. Operating margin expanded sharply, with consolidated EBITDA margin reaching 24% in Q2 compared to 15% in Q2 FY26. Growth was propelled by the Beryl acquisition, expansion in U.S. regulatory engineering services, and improved operational productivity.
உச்சம் நம்பிக்கை
என்ன மாறியதுMold-Tek reported its highest-ever quarterly profits driven by U.S. market expansion, integration of Beryl Project Engineering, and robust operational leverage.
ஏன் இது முக்கியம்H1 FY27 PAT of ₹18.62 Cr has exceeded the entire full-year PAT of FY26 (₹10.09 Cr), demonstrating strong margin expansion and successful onshore-offshore delivery.
📅 குறுகிய காலம்Strong operational momentum and substantial margin expansion are likely to support market sentiment in the near term.
📈 நீண்ட காலம்Diversification beyond traditional BIW into Data Centres, PEMB, and regulatory inspection through Beryl provides structural multi-year growth visibility in the U.S. engineering services space.
⚠ அபாய எச்சரிக்கைகள்
Vulnerability to a slowdown in U.S. construction activity or interest-rate sensitive real estate sectors
Dependency on retention of high-skill engineering talent in India and the U.S.
👀 கவனிக்க வேண்டியவை
Track the conversion of the USD 4.00 million Civil work-on-hand and monitor whether EBITDA margins can remain sustained near 24% in H2 FY27.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
Aimtron H1 FY27 Consol Revenue Up 83% YoY to ₹224.7 Cr; Net Profit Rises 73% to ₹35.2 Cr
Aimtron Electronics announced strong H1 FY27 (half-year ended September 30, 2026) financial results, with consolidated revenue from operations rising 83.3% YoY to ₹224.71 Cr compared to ₹122.58 Cr in H1 FY26. Consolidated profit after tax grew 73.5% YoY to ₹35.19 Cr from ₹20.29 Cr, supported by solid demand in its ESM & ESDM segments. The board also approved the allotment of 44,000 equity shares following the conversion of warrants, with a total of 10,38,454 warrants converted during the year out of 13,89,388 preferential warrants. As per the auditor utilization certificate, the company has raised ₹76.66 Cr of the planned ₹94.57 Cr warrant issue, deploying ₹45.48 Cr primarily across Phase 1 greenfield projects and global expansions.
உச்சம் நம்பிக்கை
என்ன மாறியதுReported H1 FY27 half-yearly results showing substantial YoY revenue and profit growth, alongside the allotment of 44,000 equity shares via warrant conversion.
ஏன் இது முக்கியம்Demonstrates sustained acceleration in the ESDM business matching management's 40-50% growth ambitions, while strengthening net worth and capacity via ongoing warrant fund deployment.
📅 குறுகிய காலம்Earnings momentum is likely to be viewed positively given the strong 83% YoY top-line expansion and healthy profitability.
📈 நீண்ட காலம்Structural tailwinds in ESDM, drone, and IoT manufacturing, combined with successful capacity additions from the ₹94.57 Cr warrant raise, support medium-term scale.
⚠ அபாய எச்சரிக்கைகள்
Dilution from conversion of remaining 3,50,934 equity share warrants
Working capital management as inventories and receivables scale alongside top-line growth
👀 கவனிக்க வேண்டியவை
Track execution of the Greenfield Phase 1 expansion and the remaining ₹31.18 Cr warrant proceeds deployment, along with the conversion timeline for the balance 3,50,934 warrants expiring March 2027.
Sundaram Finance Chairman S. Viji Steps Down After 21 Years; R. Venkatraman Appointed
Sundaram Finance Chairman and Non-Executive Director Mr. S. Viji has resigned from the board effective November 4, 2026, citing age and personal considerations. Mr. Viji served on the company's board for 40 years, including 21 years as Chairperson. The board has appointed Mr. R. Venkatraman, currently an Independent Director, as the new Chairman of the Board. The leadership transition comes at a time when the company manages an AUM of ₹55,419 crore (as of September 30, 2025) with a market capitalization of ₹45,402 crore.
உச்சம் நம்பிக்கை
என்ன மாறியதுMr. S. Viji has relinquished his role as Chairman and Non-Executive Director; Independent Director Mr. R. Venkatraman has been elected Chairman.
ஏன் இது முக்கியம்A transition in board leadership ends a 21-year chairmanship tenure at a ₹45,402 crore market cap NBFC, though succession to an existing Independent Director supports governance stability.
Tenure on Board: 40 yearsTenure as Chairperson: 21 yearsEffective date of resignation: 4th நவம்பர், 2026Company Market Cap: Rs 45402 கோடி
📅 குறுகிய காலம்Neutral market impact expected as the leadership transition is smooth and internally filled by an existing Independent Director.
📈 நீண்ட காலம்Limited operational disruption expected given Sundaram Finance's established professional management framework, though board-level guidance shifts will be observed.
⚠ அபாய எச்சரிக்கைகள்
Leadership succession and loss of long-term board institutional memory
👀 கவனிக்க வேண்டியவை
Track upcoming board meetings and corporate commentary from new Chairman R. Venkatraman regarding governance, capital allocation, and long-term strategic direction.
Sumit Woods Q2 FY27 Standalone PAT Jumps 244% YoY to ₹1.90 Cr; Revenue Triples to ₹36.62 Cr
Sumit Woods reported its Q2 FY27 (quarter ended September 30, 2026) standalone financial results, posting revenue from operations of ₹36.62 Cr, up 235% YoY from ₹10.92 Cr in Q2 FY26. Standalone net profit rose 244% YoY to ₹1.90 Cr compared to ₹0.55 Cr in the year-ago period, though down sequentially from ₹4.33 Cr in Q1 FY27. For H1 FY27, revenue reached ₹81.09 Cr compared to ₹52.35 Cr in H1 FY26, with PAT rising to ₹6.24 Cr from ₹3.96 Cr. The company also reported forfeiting ₹50.31 lakh upon the lapse of 1.75 lakh unexercised convertible warrants.
உச்சம் நம்பிக்கை
என்ன மாறியதுApproved and declared unaudited standalone and consolidated financial results for Q2 and H1 FY27 along with the limited review report.
ஏன் இது முக்கியம்Demonstrates strong YoY execution recovery in operational revenue and earnings, though the cyclical nature of real estate revenue recognition causes sequential volatility.
Q2 FY27 Revenue from operations: ₹3,661.60 லட்சம்Q2 FY27 Net Profit: ₹190.32 லட்சம்H1 FY27 Revenue vs TTM Revenue: ~83%Forfeited warrant amount: ₹50.31 லட்சம்Intangible WIP write-off: ₹49.78 லட்சம்
📅 குறுகிய காலம்Earnings show sharp YoY improvement, which may provide near-term sentiment support, though sequential contraction in profit reflects real estate lumpiness.
📈 நீண்ட காலம்Structural performance depends on project execution speed in Mumbai redevelopment projects (under DCPR 2034) and collection of customer advances.
⚠ அபாய எச்சரிக்கைகள்
Inherent lumpiness and seasonality in revenue recognition under percentage-of-completion accounting
Non-exercise and lapse of warrants (₹50.31 lakh forfeited), indicating investor hesitation at the ₹115 issue price
₹49.78 lakh write-off of capitalised project costs due to non-recoverability
👀 கவனிக்க வேண்டியவை
Track sales velocity and project delivery timelines under percentage-of-completion accounting, particularly at flagship redevelopment projects like Sumit KMR Param.
Sundaram Finance Q2 FY27 Cons PAT Rises 5.8% YoY to ₹516.66 Cr; Total Income at ₹2,749.34 Cr
Sundaram Finance reported Q2 FY27 (quarter ended September 30, 2026) consolidated total income of ₹2,749.34 crore, up 14.5% YoY from ₹2,400.68 crore in Q2 FY26. Consolidated Profit After Tax (PAT) for the quarter grew 5.8% YoY to ₹516.66 crore compared to ₹488.12 crore in the prior year period, though down from ₹636.19 crore in Q1 FY27. On a standalone basis, PAT stood at ₹475.07 crore against ₹394.20 crore in Q2 FY26, showing a 20.5% YoY rise. For H1 FY27, consolidated PAT reached ₹1,152.85 crore compared to ₹963.33 crore in H1 FY26.
உச்சம் நம்பிக்கை
என்ன மாறியதுSundaram Finance reported its Q2 and H1 FY27 financial performance along with confirmation of full utilization of NCD proceeds raised in the quarter.
ஏன் இது முக்கியம்Demonstrates consistent top-line growth above 14% YoY, though consolidated profit growth moderated sequentially due to higher finance costs and associate/JV profit swings.
Consolidated Q2 Total Income: ₹2,749.34 கோடிConsolidated Q2 PAT: ₹516.66 கோடிStandalone Q2 PAT: ₹475.07 கோடிH1 FY27 Consolidated PAT: ₹1,152.85 கோடிLoans Acquired from Subsidiary: ₹725.88 கோடி
📅 குறுகிய காலம்Earnings show resilient YoY growth, but the sequential dip in consolidated PAT from Q1 FY27 (₹636.19 cr to ₹516.66 cr) may temper near-term stock reaction.
📈 நீண்ட காலம்Sundaram Finance maintains its steady compounding trajectory with robust capitalization and a conservative balance sheet strategy.
⚠ அபாய எச்சரிக்கைகள்
Consolidated finance costs increased to ₹1,314.05 cr in Q2 FY27 from ₹1,175.97 cr YoY
Joint venture share turned negative at -₹40.58 cr for Q2 FY27 vs +₹75.12 cr in Q1 FY27
👀 கவனிக்க வேண்டியவை
Track asset quality metrics, credit costs, and commercial vehicle disbursement momentum in subsequent investor disclosures to assess margin pressure.
Thangamayil Jewellery Q2 Net Profit Reaches ₹59.45 Cr; Appoints CFO as Whole-Time Director
Thangamayil Jewellery reported standalone net profit of ₹59.45 Cr (₹5,945 lakh) for Q2 ended September 30, 2026, compared to ₹40.48 Cr (₹4,048 lakh) in the prior-year period. Total income from operations stood at ₹2,387.64 Cr (₹238,764 lakh) for the quarter. For the half-year (H1 FY27), net profit reached ₹144.55 Cr on total operating income of ₹5,043.31 Cr. The Board also approved the appointment of CFO Mr. B. Rajesh Kanna as Whole-Time Director and Mr. K. Thiagarajan as Independent Director for a 5-year term.
உச்சம் நம்பிக்கை
என்ன மாறியதுThangamayil Jewellery approved its Q2 and H1 FY27 financial results and appointed CFO B. Rajesh Kanna as an Additional Director (Whole-Time Director).
ஏன் இது முக்கியம்H1 FY27 net profit of ₹144.55 Cr already surpasses the prior TTM PAT (₹136 Cr), showing strong operational growth and improved capital efficiency with ROCE rising to 18.95%.
Q2 Net Profit: ₹59.45 கோடிQ2 Total Income from Operations: ₹2,387.64 கோடிH1 Net Profit: ₹144.55 கோடிH1 ROCE: 18.95%H1 Total Debt / Borrowings: ₹1,415 கோடி
📅 குறுகிய காலம்The market is likely to react positively to strong quarterly earnings expansion and EPS growth of ₹19.13 for the quarter.
📈 நீண்ட காலம்Expansion into urban centers and higher-margin diamond/platinum segments continue to lift operating return metrics, though high working capital debt remains a key structural factor to track.
⚠ அபாய எச்சரிக்கைகள்
Higher leverage with borrowings at ₹1,415 Cr to support working capital and inventory
Exposure to gold price volatility and inventory holding cycles
👀 கவனிக்க வேண்டியவை
Monitor whether the strong sales velocity and ROCE trajectory sustain through the upcoming festive and wedding quarters, alongside the planned store additions in the Chennai market.
Manika Plastech Approves Q2 FY27 Results; Reports Zero Deviation in ₹92.50 Cr IPO Fund Use
Manika Plastech Limited's Board of Directors approved the unaudited standalone and consolidated financial results for the quarter and half-year ended September 30, 2026. The company also confirmed zero deviation in the utilisation of proceeds from its ₹92.50 crore fresh issue IPO allotted on September 17, 2026. Out of the net proceeds of ₹81.64 crore, ₹8.06 crore has been deployed towards plant and machinery capex (against ₹54.93 crore allocated) and ₹3.61 crore toward debt repayment (against ₹15.00 crore allocated). An amount of ₹7.32 crore was utilised for general corporate purposes, while ₹7.21 crore was incurred on issue expenses.
உச்சம் நம்பிக்கை
என்ன மாறியதுBoard approved Q2 FY27 unaudited results and submitted the quarterly statement confirming adherence to IPO fund utilisation objects.
ஏன் இது முக்கியம்Confirms IPO proceeds are being deployed as committed in the prospectus, particularly for capacity additions through plant and machinery purchases.
📅 குறுகிய காலம்Neutral trading response anticipated as the filing is routine compliance post-IPO with clean utilisation reporting.
📈 நீண்ட காலம்Execution of the remaining ₹46.87 crore plant and machinery capex will determine future volume growth and operating scale.
⚠ அபாய எச்சரிக்கைகள்
Execution timeline for plant and machinery commissioning
👀 கவனிக்க வேண்டியவை
Track the detailed financial tables in the Annexure-A results to assess revenue and profitability, and monitor ongoing deployment of the remaining ₹46.87 crore allocated for plant and machinery capex.
MOL Q2 FY27 Revenue Up 18% YoY to ₹658.2 Cr; EBITDA Margin Contracts to 10.8%
Meghmani Organics Limited reported an 18% YoY increase in standalone revenue from operations to ₹658.2 crore for Q2 FY27, compared to ₹557.7 crore in Q2 FY26. EBITDA was nearly flat at ₹70.9 crore (up 1% YoY), with EBITDA margins contracting from 12.6% to 10.8% due to elevated input and logistics costs. Net profit rose 6% YoY to ₹45.3 crore. Additionally, the company announced that it has received NCLT approval to amalgamate two wholly owned subsidiaries into MOL.
உச்சம் நம்பிக்கை
என்ன மாறியதுMOL announced its Q2 FY27 standalone earnings and confirmed NCLT approval for the merger of two wholly owned subsidiaries.
ஏன் இது முக்கியம்Demonstrates solid volume and top-line growth (18% YoY), but shows margin compression from cost inflation that offset operating leverage.
Q2 FY27 Revenue from Operations: ₹658.2 கோடிQ2 FY27 Net Profit: ₹45.3 கோடிQ2 FY27 EBITDA Margin: 10.8%H1 FY27 Net Profit: ₹102.9 கோடிQ2 வருவாய் vs TTM வருவாய்: ~31.3%
📅 குறுகிய காலம்Top-line recovery is evident, but margin compression may temper immediate investor sentiment over the next few sessions.
📈 நீண்ட காலம்The subsidiary amalgamation should provide operational synergies and cost efficiencies, while margin recovery hinges on easing raw material and logistics pressures.
⚠ அபாய எச்சரிக்கைகள்
Sharp increase in input and logistics costs compressing operating margins
Flat realisations limiting pricing power
👀 கவனிக்க வேண்டியவை
Track whether elevated input and logistics costs continue to pressure margins in Q3 FY27, and monitor realization trends in the Crop Protection and Pigment segments.
SANDUMA Q2FY27 Presentation: Cons. PAT Surges 88% YoY to ₹261 Cr; Mining EC Expansion Applied
Sandur Manganese & Iron Ores Limited released its Q2FY27 investor presentation, reporting consolidated total income of ₹1,519 crore (up 22% YoY) and consolidated PAT of ₹261 crore (up 88% YoY). Iron ore sales volume surged 59% YoY to 12.45 lakh tonnes, while manganese ore realisations increased 7% QoQ to ₹8,502/tonne. The company has applied for an enhancement in Environmental Clearance (EC) for iron ore production from 7.85 MTPA to 9.42 MTPA. Arjas Steel Private Limited was rebranded to Royal Sandur Metals Private Limited.
உச்சம் நம்பிக்கை
என்ன மாறியதுReleased comprehensive performance presentation for Q2FY27 detailing volume growth in iron ore, margin expansion, and operational updates across subsidiaries.
ஏன் இது முக்கியம்Demonstrates robust cash flow generation and successful integration of downstream specialty steel (rebranded as Royal Sandur Metals), supported by volume growth in captive iron ore mining.
📅 குறுகிய காலம்Operating momentum is likely to be viewed favorably given sharp margin improvement and 59% volume jump in iron ore sales.
📈 நீண்ட காலம்The integration of specialty steel downstream, along with potential iron ore expansion to 9.42 MTPA and the 7 MTPA beneficiation plant scheduled for Q2FY28, provides structural volume and margin support.
⚠ அபாய எச்சரிக்கைகள்
Forest lease validity requires compliance with compensatory afforestation before December 2026
Iron ore realizations softened 4% QoQ to ₹2,975/tonne
👀 கவனிக்க வேண்டியவை
Track the regulatory approval from the Department of Mines and Geology for the Downhill Conveyor System weighbridge integration, as well as the progress on the EC hike application to 9.42 MTPA.
Smarten H1 FY27 Revenue Jumps 77.5% YoY to ₹204.54 Cr, PAT More Than Doubles to ₹11.99 Cr
Smarten Power Systems reported strong consolidated H1 FY27 results with revenue from operations surging 77.5% YoY to ₹204.54 crore compared to ₹115.26 crore in H1 FY26. EBITDA grew 148.7% YoY to ₹17.02 crore, with EBITDA margin expanding by 238 bps to 8.3%. Net profit rose 103.9% YoY to ₹11.99 crore, with annualised ROCE and ROE reaching 33.12% and 25.07%, respectively. The company also reported ~80% capacity utilization at its acquired Baddi lead-acid battery plant.
உச்சம் நம்பிக்கை
என்ன மாறியதுSmarten Power Systems published its comprehensive investor presentation detailing H1 FY27 financial performance and strategic segment updates.
ஏன் இது முக்கியம்Demonstrates rapid scale-up in revenue and operational profitability driven by backward integration (battery manufacturing at Baddi) and rooftop solar market expansion.
📅 குறுகிய காலம்The strong H1 operational and margin numbers provide positive sentiment, highlighting accelerating volume delivery in solar and power back-up segments.
📈 நீண்ட காலம்Backward integration into battery manufacturing and expansion into corporate/project sales positions the firm well to capture growth from rooftop solar schemes (PM Surya Ghar).
⚠ அபாய எச்சரிக்கைகள்
High vulnerability to raw material and electronic component cost swings (materials consumed comprise ~77% of sales)
Significant working capital tied up with inventories at ₹54.96 crore and trade receivables at ₹37.40 crore
👀 கவனிக்க வேண்டியவை
Track the progress on the planned new inverter plant scheduled for completion by March 2027 and watch raw material margin pressures as input costs represent over 77% of revenue.
Sangam India Q2 FY27 PAT Jumps 131% YoY to ₹53 Cr; Plans ₹1,500 Cr Capex by FY29
Sangam (India) Limited released its Q2 & H1 FY27 investor presentation, reporting a 33% YoY increase in Q2 FY27 consolidated revenue to ₹1,045 Cr and a 130.9% YoY surge in PAT to ₹53 Cr. Operating performance strengthened with EBITDA climbing 67.6% YoY to ₹127 Cr and EBITDA margins expanding 250 bps to 12.1%. The company outlined an ambitious capex roadmap of approximately ₹1,500 Cr through March 2029 (~50% of current market cap of ₹2,986 Cr) to expand modern manufacturing and renewable energy capabilities. Net debt as of September 2026 stood at ₹1,373 Cr, while credit rating was upgraded to IND A / Stable by India Ratings in October 2026.
உச்சம் நம்பிக்கை
என்ன மாறியதுSangam released detailed Q2/H1 FY27 operational performance and announced an ongoing ~₹1,500 Cr capex plan targeting modern manufacturing and renewable power by March 2029.
ஏன் இது முக்கியம்Demonstrates strong operational turnaround with H1 FY27 PAT (₹94 Cr) already surpassing full-year FY26 PAT (₹83 Cr), though aggressive capex and working capital have increased net debt to ₹1,373 Cr.
📅 குறுகிய காலம்Positive operational sentiment given strong earnings growth and margin expansion, balanced against higher debt and elongated receivable days (77 days).
📈 நீண்ட காலம்The ₹1,500 Cr expansion and shift toward renewable power (targeting 70% green share by Q1 FY28) could structurally reduce costs and expand capacity, provided leverage remains manageable.
⚠ அபாய எச்சரிக்கைகள்
Negative net cash flow from operating activities (-₹41 Cr in H1 FY27) due to ₹263 Cr working capital lock-up.
Rising net debt reaching ₹1,373 Cr, increasing leverage risk amid capital expenditure.
👀 கவனிக்க வேண்டியவை
Monitor cash flow generation and working capital normalization as H1 FY27 operating cash flow was negative ₹41 Cr due to working capital expansion. Track progress on the ₹1,500 Cr capex rollout and debt levels over upcoming quarters.
Q2 FY27 Consolidated PAT at ₹22.22 Cr, Revenue Up 10.6% YoY to ₹640.22 Cr
Unichem Laboratories reported consolidated revenue from operations of ₹640.22 Cr for Q2 FY27 (quarter ended Sep 30, 2026), up 10.6% YoY from ₹578.96 Cr in Q2 FY26 and 1.2% QoQ. Consolidated net profit stood at ₹22.22 Cr, recovering from a net loss of ₹11.89 Cr in the year-ago period, though down 46.4% sequentially from ₹41.47 Cr in Q1 FY27. Profitability was affected by an exceptional expense of ₹24.26 Cr provision for claims during the quarter. For H1 FY27, revenue reached ₹1,272.84 Cr with PAT of ₹63.69 Cr.
உச்சம் நம்பிக்கை
என்ன மாறியதுUnichem reported Q2 FY27 earnings showing sustained YoY top-line growth and a turnaround from YoY losses, albeit burdened by a ₹24.26 Cr exceptional provision.
ஏன் இது முக்கியம்Demonstrates operational stabilization with annual run-rate revenue approaching ~₹2,500 Cr, though cash flow from operations turned negative due to inventory and receivable buildup.
Q2 FY27 Revenue from operations: ₹640.22 கோடிQ2 FY27 Net Profit after tax: ₹22.22 கோடிQ2 FY27 Exceptional items: ₹24.26 கோடிH1 FY27 Cash flow from operations: ₹(68.07) CrQ2 வருவாய் vs TTM வருவாய்: ~27.7%
📅 குறுகிய காலம்Market reaction may be muted to slightly cautious given the sequential drop in PAT and negative operating cash flow generation in H1 FY27.
📈 நீண்ட காலம்Long-term trajectory depends on sustained margin expansion across US and international generic markets alongside synergy extraction with the Ipca group.
⚠ அபாய எச்சரிக்கைகள்
Negative operating cash flow of ₹(68.07) Cr in H1 FY27 due to working capital blockages
Exceptional provision for claims of ₹24.26 Cr impacting net profit
👀 கவனிக்க வேண்டியவை
Track operating cash flow recovery in H2 FY27 as working capital adjustments stretched cash flows, and monitor details regarding the nature of the ₹24.26 Cr exceptional provision for claims.
Q2 FY27 PAT Rises 44.8% YoY to ₹143.5 Cr; Quarterly Revenue Crosses ₹900 Cr Milestone
Marksans Pharma reported a 30.5% YoY rise in operating revenue to ₹940.2 crore for Q2 FY27, crossing ₹900 crore in quarterly revenue for the first time. Operating EBITDA rose 48.3% YoY to ₹214.3 crore with margins expanding 274 bps to 22.8%, while PAT increased 44.8% YoY to ₹143.5 crore. For H1 FY27, PAT nearly doubled to ₹302.9 crore (up 92.5% YoY), reaching over 70% of the entire FY26 net profit (₹420 crore). The balance sheet remains robust with net cash expanding to ₹1,095 crore and H1 operating cash flow surging 4.3x to ₹322 crore.
உச்சம் நம்பிக்கை
என்ன மாறியதுMarksans Pharma published its Q2 and H1 FY27 earnings press release, demonstrating quarterly revenue above ₹900 crore and EBITDA of ₹214.3 crore.
ஏன் இது முக்கியம்Topline and margin expansion reflect successful integration of acquired assets, organic volume growth in the UK and US, and significant operating cash flow generation.
📅 குறுகிய காலம்Strong operational beat YoY is likely to support positive market sentiment, though sequential PAT softened 10.0% QoQ from ₹159.4 crore in Q1 FY27.
📈 நீண்ட காலம்With net cash of ₹1,095 crore and expanding European and US footprint, the company is structurally positioned to execute strategic M&A and sustain organic formulations growth.
Pricing erosion risks in Rx portfolios and US consumer environment softness
👀 கவனிக்க வேண்டியவை
Track management commentary in the earnings conference call scheduled for November 5, 2026, focusing on gross margin sustainability and the integration of European front-end QliniQ.
MOL Q2 Standalone Net Profit Rises 5.6% YoY to ₹45.32 Cr; Revenue at ₹658.21 Cr
Meghmani Organics Limited (MOL) reported standalone revenue from operations of ₹658.21 Cr for Q2 FY27 (ended September 30, 2026), marking an 18.0% YoY increase from ₹557.66 Cr in Q2 FY26 and a 25.9% QoQ increase. Standalone net profit stood at ₹45.32 Cr, up 5.6% YoY compared to ₹42.92 Cr in Q2 FY26, though down 21.3% QoQ from ₹57.60 Cr. Total expenses climbed to ₹620.77 Cr, primarily driven by higher raw material costs of ₹438.54 Cr. Basic EPS for the quarter was reported at ₹1.78 per share compared to ₹1.69 in the year-ago period.
உச்சம் நம்பிக்கை
என்ன மாறியதுMOL approved and released its standalone and consolidated unaudited financial results for Q2 and H1 ended September 30, 2026.
ஏன் இது முக்கியம்Demonstrates top-line recovery and reduced finance costs YoY, although raw material expenses have expanded, putting pressure on sequential profit margins.
Standalone Revenue (Q2): ₹65,820.88 லட்சம்Standalone Net Profit (Q2): ₹4,532.16 லட்சம்Basic EPS (Q2): ₹1.78Finance Costs (Q2): ₹1,115.14 லட்சம்
📅 குறுகிய காலம்Market sentiment may react mildly positively to steady YoY revenue and profit growth, tempered by sequential margin contraction.
📈 நீண்ட காலம்Sustained long-term growth will depend on volume expansion from the Titanium Dioxide (TiO2) and Nano Urea projects against Chinese supply competition.
⚠ அபாய எச்சரிக்கைகள்
Raw material cost volatility (cost of materials consumed rose ~28.3% YoY)
Sequential dip in net profit (down from ₹57.60 Cr in Q1 FY27 to ₹45.32 Cr in Q2 FY27)
👀 கவனிக்க வேண்டியவை
Track the full consolidated performance report and management commentary regarding raw material inflation and price realization in export markets.
Marksans Pharma Reports Q2 FY27 Results; Acquires European Entities QliniQ & ABCnow for €8.6M
Marksans Pharma declared its Q2 and H1 FY27 results (period ended September 30, 2026), with standalone H1 FY27 revenue from operations at ₹7,042.41 million compared to ₹6,309.91 million in H1 FY26. Standalone net profit for Q2 FY27 stood at ₹855.42 million versus ₹690.92 million in Q2 FY26. Alongside results, the company completed two strategic European acquisitions: 100% of Netherlands-based QliniQ B.V. for EUR 7.50 million and Germany-based ABCnow GmbH for EUR 1.10 million to build direct frontend distribution.
உச்சம் நம்பிக்கை
என்ன மாறியதுMarksans Pharma released its Q2/H1 FY27 financial results and officially reported two European frontend acquisitions (QliniQ B.V. and ABCnow GmbH) totaling EUR 8.60 million.
ஏன் இது முக்கியம்The acquisitions provide direct sales and distribution capabilities in the Netherlands and Germany, advancing the company's European footprint beyond the UK.
📅 குறுகிய காலம்Solid operational performance and European market expansion provide steady momentum over the coming weeks.
📈 நீண்ட காலம்Direct distribution access in Germany and the Netherlands structurally enhances operating leverage and reduces dependence on intermediaries and the UK market.
⚠ அபாய எச்சரிக்கைகள்
Provisional purchase price allocations under Ind AS 103 pending final fair value determination
Integration risks in foreign markets (Germany, Netherlands)
👀 கவனிக்க வேண்டியவை
Track the integration and margin profile of newly acquired European subsidiaries (QliniQ and ABCnow) and monitor ramp-up of the Teva manufacturing facility.
Marushika H1 FY27 PAT Jumps 126% YoY to ₹7.04 Cr; Bags ₹30 Cr Nasik Kumbh Project
Marushika Technology Limited released its H1 FY27 investor presentation, reporting a 71.59% YoY rise in revenue from operations to ₹83.46 crore compared to ₹48.64 crore in H1 FY26. Net profit (PAT) grew 126.29% YoY to ₹7.04 crore, with PAT margins expanding by 204 bps to 8.44%. The company highlighted key project wins, including a ₹30 crore Smart Parking contract for Nasik Kumbh (with consortium partners) executable by July 2027. It also reported the completion of the ₹24.83 crore Rail Cloud project and ~85% execution status on the ₹31.19 crore Delhi Metro Phase-IV project.
உச்சம் நம்பிக்கை
என்ன மாறியதுMarushika disclosed its detailed H1 FY27 financial presentation along with updates on major municipal and highway project wins.
ஏன் இது முக்கியம்Demonstrates strong top-line and margin acceleration while expanding the order pipeline across smart city and government infrastructure projects.
H1 FY27 Revenue: ₹83.46 கோடிH1 FY27 PAT: ₹7.04 கோடிEBITDA லாப வரம்பு: 12.29%Nasik Kumbh Order Value: ₹30 கோடிTrade Receivables as of Sep 2026: ₹58.23 கோடி
📅 குறுகிய காலம்Market sentiment is likely to react positively to the strong 126% PAT growth and large project disclosures.
📈 நீண்ட காலம்Expansion into AI medical robotics distribution and consistent smart infrastructure wins indicate broadening execution capabilities, though working capital management remains key.
⚠ அபாய எச்சரிக்கைகள்
High working capital intensity with trade receivables at ₹58.23 crore representing a large portion of H1 revenue
Consortium dependency and execution risks for the ₹30 crore municipal project
👀 கவனிக்க வேண்டியவை
Track execution progress and margin delivery on the ₹30 crore Nasik Kumbh project and Delhi Metro completion ahead of H2 FY27 results.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
